Metagenomi Therapeutics, Inc.
$1.53
▲
0.75%
2026-04-21 08:08:01
metagenomi.co
NMS: MGX
Explore Metagenomi Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$55.68 M
Current Price
$1.53
52W High / Low
$3.95 / $1.25
Stock P/E
—
Book Value
$4.22
Dividend Yield
—
ROCE
-48.45%
ROE
-44.66%
Face Value
—
EPS
$-2.36
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
119
Beta
0.57
Debt / Equity
25.64
Current Ratio
7.22
Quick Ratio
7.22
Forward P/E
-0.83
Price / Sales
2.06
Enterprise Value
$-68.23 M
EV / EBITDA
0.75
EV / Revenue
-2.71
Rating
None
Target Price
$9.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | IO Biotech, Inc. | $0.01 | — | $0.55 M | — | -197.41% | -2.4% | $2.79 / $0.01 | $0.01 |
| 2. | YD Bio Ltd | $5.31 | — | $382.42 M | — | -22.15% | -42.69% | $31 / $5.12 | $4.57 |
| 3. | BeyondSpring Inc. | $1.78 | — | $73 M | — | -72.39% | 3.09% | $3.44 / $1.21 | $-0.8 |
| 4. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
| 5. | Satellos Bioscience Inc. | $7.83 | — | $248.1 M | — | -95.23% | -66.37% | $18.98 / $6.24 | $1.8 |
| 6. | Lunai Bioworks Inc. | $0.34 | — | $12.33 M | — | 88.63% | -3.66% | $5.5 / $0.15 | $-0.56 |
| 7. | Traws Pharma, Inc. | $1.39 | — | $14.12 M | — | -185.49% | -10.6% | $3.27 / $0.97 | $0.64 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 3.91 M | 8.66 M | 8.51 M | 4.13 M | 9.61 M | — |
| Operating Profit | -24.37 M | -22.84 M | -20.99 M | -27.82 M | -20.62 M | — |
| Net Profit | -22.53 M | -20.39 M | -19.91 M | -25.04 M | -23.4 M | — |
| EPS in Rs | -0.6 | -0.54 | -0.53 | -0.67 | -0.62 | -0.51 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 25.21 M | 52.3 M | 44.76 M | 17.2 M |
| Operating Profit | -96.01 M | -88.9 M | -78.49 M | -44.64 M |
| Net Profit | -87.87 M | -78.06 M | -68.25 M | -43.59 M |
| EPS in Rs | -2.34 | -2.07 | -1.81 | -1.16 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 221.1 M | 324.6 M | 364.84 M | 414.49 M |
| Total Liabilities | 62.51 M | 89.74 M | 500.43 M | 488.91 M |
| Equity | 158.6 M | 234.86 M | -135.58 M | -74.43 M |
| Current Assets | 165.54 M | 257.96 M | 278.27 M | 366.9 M |
| Current Liabilities | 22.93 M | 37.31 M | 68.86 M | 48.54 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -88.89 M | -109.07 M | -91.41 M | 29.72 M |
| Investing CF | 103.53 M | -88.16 M | 45.73 M | -122.2 M |
| Financing CF | -0.36 M | 84.01 M | 1.01 M | 239.59 M |
| Free CF | -89.47 M | -112.19 M | -101.22 M | 15.75 M |
| Capex | -0.57 M | -3.11 M | -9.81 M | -13.98 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 16.84% | 160.21% | — | — |
| Earnings Growth % | -14.36% | -56.57% | — | — |
| Profit Margin % | -149.26% | -152.5% | -253.45% | — |
| Operating Margin % | -170% | -175.38% | -259.53% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -159.66% | -165.98% | -227.87% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.